Current and future therapies for HCV infection: what should the end point for treatment be?
Based upon all of the available data relating to the natural history, chemical course, and response to therapy of HCV, the following recommendations are made: 1) The primary end point for HCV therapy should be HCV clearance from all tissue sites, eg plasma, liver and others 2) Therapy should be provided for patients with early infections as they have the best chance of achieving a virologic response 3) Therapy should be offered to patients with cirrhotic disease, as prevention of hepatic decompensation and degeneration to hepatic cancer is possible 4) End stage decompensated disease should be treated, particularly if liver transplantation is being considered, in an effort to either eliminate or ameliorate disease recurrence 5) Combination therapies are preferable to monotherapy as they enhance the likelihood of a therapeutic response. Some of these include agents that reduce the frequency of IFN-induced untoward events (NSAIDs) 6) The approach to HCV infection should be to view it as an infectious disease. In this way, multi-agent therapy could be used to prevent the emergence of drug resistant mutants as well as to obtain earlier clearance of the infection than is possible with monotherapy.
Van Thiel
D H
DH
Transplant Center, University of Kentucky Medical Center, Chandler Medical Center, Lexington 40536-0084, USA.
De Maria
N
N
Colantoni
A
A
Idilman
R
R
D000998:Antiviral Agents / Q000627:therapeutic use; D006526:Hepatitis C / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015995:Prevalence
D000998:Antiviral Agents; D016898:Interferon-alpha